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At a glance commentary: Myocardial dysfunction is a major feature in the pathophysiology 
of septic shock. IL-6 has been identified as a key mediator of a negative inotropic state in 
meningococcal sepsis. In this study we demonstrate that the p38MAPK pathway is a central 
regulator in the negative inotropic activity of interleukin 6 and is highly dysregulated in 
meningococcal septic shock. Modulators of the p38MAPK pathway could have therapeutic 
potential for patients with cardiac dysfunction in meningococcal and other forms of septic 
shock.
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Abstract: 
Objectives: 
Myocardial failure, leading to inotrope-unresponsive shock, is the predominant cause of death in 
meningococcal and other forms of septic shock. Pro-inflammatory cytokines released in septic shock are 
known to have myocardial depressant effects. We previously showed that Interleukin 6 (IL-6) is a major 
myocardial depressant factor in children with meningococcal septicaemia. In the current study, we aimed 
to investigate the mechanisms by which IL-6 induces myocardial failure in meningococcal sepsis, and to 
identify potential novel therapeutic targets. 
Design: Laboratory based study  
Setting: University hospital and laboratories 
Patients: Children with a clinical diagnosis of meningococcal septic shock  
Methods: 
We studied IL-6-induced signaling events, both in vitro using isolated rat ventricular cardiac myocytes as a 
model of myocardial contractility, and in whole blood from children with meningococcal sepsis. 
Measurements and Main results: 
We demonstrated involvement of JAK2, PI3K, Akt and p38MAPK in IL-6-induced negative inotropy in 
isolated cardiac myocytes. Inhibition of p38MAPK not only reversed IL-6-induced myocardial depression in 
both rat and human myocytes, but restored inotrope responsiveness. Cardiomyocytes transduced with 
dominant-negative p38MAPK showed no IL-6-induced myocardial depression. To investigate p38MAPK in 
vivo, we profiled global RNA expression patterns in peripheral blood of children with meningococcal 
septicaemia. Transcripts for genes mapping to the p38MAPK pathway showed significantly altered levels of 
abundance, with a high proportion of genes of this pathway affected.  
Conclusions: Our findings demonstrate an integral role of the p38MAPK pathway in IL-6-mediated cardiac 
contractile dysfunction and inotrope insensitivity. Dysregulation of the p38MAPK pathway in 
meningococcal septicemia suggests that this pathway may be an important target for novel therapies to 
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reverse myocardial dysfunction in patients with meningococcal septic shock who are not responsive to 
inotropic support. 
 (273 words)
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Introduction: 
Sepsis and septic shock remain major causes of morbidity and mortality worldwide, with reported 
mortality rates of 10-50% [1-4]. An important feature in the pathophysiology of septic shock is the 
development of progressive hemodynamic and cardiovascular instability and depressed myocardial 
contractility [5, 6].  
Over the past three decades, intense efforts to develop immunomodulatory treatments for septic shock 
have targeted early mediators in the inflammatory cascade triggered by bacterial infection. Despite success 
in animal models, therapeutic trials of inhibitors of up-stream factors such as endotoxin [7], cytokines [8, 9] 
and key mediators of coagulation and inflammation [10, 11] have been largely disappointing. It is 
increasingly clear that by the time septic shock is recognised, hours or days after the initial onset of 
infection, downstream inflammatory pathways dominate as causal factors in the ongoing pathophysiology 
and may present more logical clinical targets for immune modulating therapies.  
Meningococcal septicaemia is among the most fulminant causes of septic shock, and is a major infectious 
cause of death in children in many developed countries. Since meningococcal sepsis generally occurs in 
otherwise healthy children and adults, it provides a unique model to study the mechanisms of septic shock. 
We previously showed that Interleukin 6 (IL-6) is a major myocardial depressant factor in meningococcal 
shock [12].  
IL-6 induces a wide range of cellular and physiological responses [13]. Upon binding to its receptor, IL-6 
causes homodimerization of the membrane-bound receptor gp130 which in turn leads to activation of 
associated protein tyrosine kinases including the Janus kinase (JAK) family [14], tyrosine phosphorylation of 
gp130 [15], and activation of multiple signal transducing factors such as signal transducer and activator of 
transcription (STAT) [16]. Following phosphorylation, STATs migrate to the nucleus where they upregulate 
transcription of a number of intracellular signaling cascades. The p38 mitogen-activated protein kinase 
(MAPK) [17] and phosphatidylinositol 3-kinase (PI3K) [18] pathways are known to be activated in cardiac 
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myocytes following inflammatory activation. The functional significance of these intracellular signaling 
pathways in the context of IL-6 mediated negative inotropy in sepsis is not well defined. We set out to 
investigate the role of key downstream signaling mediators in the myocardial depression induced by IL-6.  
Methods: 
We undertook a series of in vitro and in vivo studies to explore the pathway of IL-6 induced myocardial 
depression in meningococcal sepsis (Figure 1). 
Patients and controls 
 Children were enrolled in the study at the time of admission to the Intensive Care Unit with suspected 
meningococcal sepsis. Following informed parental consent, and with approval of the hospital Local 
Research Ethics Committee, venous blood was collected on admission to the PICU. Diagnosis was 
confirmed by isolation of the organism from blood, CSF, or by PCR amplification of meningococcal DNA 
from peripheral blood, as described previously [19]. Venous blood samples from healthy adult volunteers 
were obtained following informed consent.  
Biological and chemical reagents 
Antibodies to p38MAPK, phospho-p38MAPK, Akt, phospho-Akt, STAT3 and phospho-STAT3 were obtained 
from Cell Signaling Technology (Danvers, MA). IL-6 was obtained from Biomyx Technology (San Diego, CA). 
All other chemicals were purchased from Sigma-Aldrich (Gillingham, UK). 
Isolation of Adult rat and human ventricular myocytes 
All studies complied with the United Kingdom Home Office Regulation Governing the Care and Use of 
Laboratory Animals. Ventricular myocytes were isolated from adult male Sprague–Dawley rats (250-350 
grams) by collagenase digestion, using the standard enzymatic technique as previously described [12]. 
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Human tissue from the left or right ventricle was obtained from explanted hearts in adult patients 
undergoing cardiac transplantation following informed consent. Procedures for collecting human heart 
tissue conformed to the Ethics Committee requirements of the Royal Brompton and Harefield Hospital, UK. 
Tissue was immediately placed in cardioplegia solution at 4°C and ventricular myocytes isolated using a 
standard enzymatic technique [12]. 
For adenoviral transfection, cells were infected with adenovirus at a multiplicity of infection of 500 for the 
dominant negative p38MAPK (Ad. p38DN) construct, which had the phosphorylation motif (T-G-Y) mutated 
to (A-G-F) (kindly provided by Drs Menick, Charleston and Wang, University of California, San Diego). Cells 
were incubated at 37°C for 48 hours before use in myocyte contraction assays. 
Myocyte Contraction Measurements 
Myocyte contraction experiments were performed as previously described [12]. In brief, cells in Kerbs–
Henseleit (KH) solution equilibrated to pH 7·4 with 95% O2-5% CO2 were placed in a perspex chamber on 
the stage of an inverted microscope. Myocytes were left for 10 minutes to allow time for adherence to the 
cover slip. After this time, cells were perfused with KH solution supplemented with calcium (1-2 mM, rat; 
2-6 mM, human). Experiments were carried out at 37°C with field stimulation at 0·5 Hz in rat myocytes, 
while human myocytes were paced at 0·2 Hz, 32ºC. Individual cells were digitally tracked and the 
contraction amplitude measured continually using video edge detection as previously described [12] (Ion 
Optix , MA, USA). Myocyte contraction was expressed as the percentage shortening of cell length upon 
field stimulation.  
Analysis of the IL-6 signaling pathway using inhibitors of key intracellular mediators. 
To obtain a model that closely resembled the clinical situation of septic shock, where patients are 
supported with inotropic medication, we employed catecholamine stimulation. Isoprenaline (10 nM) was 
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added to perfusion buffer, and a baseline measurement taken when contraction amplitude reached a 
stable plateau..  
For evaluation of PI3K, JAK2 and p38MAPK, cells were perfused with the specific inhibitors (10µM LY94002, 
20µM AG490, 3µM SB203580 respectively) for 15 minutes before exposure to IL-6.  
To evaluate the role of Gi signaling, isolated rat ventricular myocytes were incubated with 1·5 µg/ml 
pertussis toxin (an inhibitor of this pathway) for 24 hours and then used in contraction assays. For 
individual myocytes, the efficiency of Gi inactivation was confirmed by carbachol challenge in the presence 
of isoprenaline.  
Western Blotting 
Western blotting was performed to identify and quantify STAT3, Akt and p38MAPK protein levels. We also 
used this method to examine p38MAPK activation in dominant negative myocytes. Cultured myocytes 
were centrifuged (14,000 g, 10 minutes, 4°C), snap frozen in liquid nitrogen and stored at -80°C. Cells were 
subsequently resuspended in Phospho-Safe extraction buffer (Novagen) and protein concentrations 
determined (Bio-Rad). Using a 10% gel, 40 µg of protein was separated by SDS-PAGE and transferred to 
PVDF membrane. Blots were incubated with antibodies to the target mediator overnight at 4°C. Secondary 
antibodies were either conjugated with horseradish peroxidise (Amersham pharmaceuticals) or 
fluorescence (QDot) to detect protein bands. Protein levels were quantified using densitometry (Gene 
Genius Gel Imaging, Syngene).  
Gene expression 
Whole blood (2·5 ml) from patients and controls was collected into RNA stabilisation fluid (PaxGene Blood 
RNA tubes, Beckton Dickinson). Patient samples were obtained on admission to the ICU within 24 hours of 
clinical presentation. Total RNA was extracted using PreAnalytix RNA extraction kit (Qiagen, Crawley, UK).  
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After linear amplification (MessageAmp II, Applied Biosystems), and reverse transcription to cDNA, sample 
cDNA was labelled with Cy5-dUTP, and combined with Cy3-dUTP-labelled reference cDNA (Stratagene)  
[20]. Samples were then washed, concentrated, and hybridised to custom-printed cDNA microarrays 
containing 37632 elements representing approximately 18000 unique human genes [21]. The hybridized 
slides were scanned using a GenePix 4000A microarray scanner (Axon Instruments), with every spot on the 
array given a relative fluorescence ratio for sample and reference RNA. Areas of the array with blemishes 
or poor quality were excluded from analysis using GenePix Pro 6.0 (Axon Instruments).  
For the rat microarray experiment, isolated cardiac ventricular myocytes were cultured in M199 medium 
with addition of 5 mM creatine, 5 mM taurine, 2 mM carnitine, 0.1 M insulin, 100 mM ascorbate and 
penicillin/streptomycin. Cells were incubated with recombinant human IL-6 (20ng/ml) or in medium alone 
for 6 hours at 37°C. Myocyte RNA was extracted using the RNEasy extraction kit (Qiagen, Crawley, UK). 
RNA was amplified and labelled using the Illumina TotalPrep RNA Amplification Kit (Applied Biosystems), 
and hybridised to the RatRef-12 Expression BeadChip (Illumina).  Arrays were scanned using a BeadArray 
Reader (Illumina) and probe IDs associated with intensity data using BeadStudio v3.1.3.0 
The datasets discussed in this publication have been deposited in the Stanford Microarray Database and 
Array Express under accession number E-MTAB-344. 
Statistics 
All quantitative data are expressed as median ± IQR. Continuous data were analysed using the Wilcoxon 
signed rank test to compare control and experimental conditions. A value of p< 0·05 was considered 
statistically significant.  
Raw expression data from 37 individuals (23 healthy controls, 14 patients) were downloaded from Stanford 
Microarray Database. Data were filtered to include array elements that were present on more than 80% of 
the arrays. Within-slide normalization was performed through within-print-tip-group intensity dependent 
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location normalization using the loess function, to correct for systematic variation that is introduced by the 
overall spot intensity, dye and spatial effects. Scale normalization was applied to equalize the range of log2 
ratios ďetǁeeŶ slides. DiffereŶtial eǆpressioŶ aŶalǇsis folloǁed a ͞Tǁo-Groups: CoŵŵoŶ RefereŶĐe͟ 
experimental design and was performed using Limma [22]. Linear models were fitted and moderated t-
statistics were calculated for each gene. Adjustment for multiple hypothesis testing was performed via the 
Benjamini and Hochberg method that controls the false discovery rate [23]. The significance level was set 
to α=Ϭ.Ϭϱ. EŶriĐhŵeŶt of the pϯ8MAPK pathǁaǇ, ǁas assessed ďǇ the hǇpergeoŵetriĐ distriďutioŶ 
;FisĐher’s eǆaĐtͿ. The aŶalǇsis ǁas ĐoŶduĐted ǁith the use of BioĐoŶduĐtor softǁare paĐkages iŶ R.  
In order to investigate the role of p38MAPK in the clinical pathophysiology of meningococcal sepsis, we 
used whole genome RNA expression profiling to study the regulation of activators and downstream 
effectors of p38MAPK. We identified genes widely accepted as being part of the p38MAPK signaling 
pathway using KEGG,[24] Panther version 6·1,[25] IŶgeŶuitǇ PathǁaǇs AŶalǇsis ϲ aŶd GeŶeAssist™ PathǁaǇ 
Atlas (www.ambion.com)), as well as published literature and websites,[24, 26-30] (www.cellsignal.com). 
Results 
Patients  
There were 14 children (aged 2 months to 16 years of age) included in the study, 8 children were female, 6 
were male. Median age was 51 months (Interquartile range 21-157 months). There were 2 deaths (14.3%). 
All patients had clinical evidence of meningococcal septicaemia with petecchiae or purpura. Some had 
additional signs or symptoms of meningitis. 
IL-6 reduces both basal cardiac myocyte contractility and inotrope responsiveness. 
Addition of 20 ng /ml IL-6 (the median serum level of IL-6 seen in our patients in a previous study [12]) to 
the perfusion buffer not only acutely depressed basal myocyte contraction as previously shown, but 
significantly diminished inotrope sensitivity. After establishing baseline myocyte contractility for 15 
minutes, addition of isoprenaline (30nM) to the perfusion buffer increased myocyte contraction amplitude 
10 
by 52% : from 6·1% (IQR  3.9 - 8.5) to 9·3% (IQR 6.7 - 11.7), n=45. After 15 minutes, IL-6 was added to the 
perfusion buffer, significantly decreasing myocyte contraction by 19.9% to 7.45% (IQR 6.0-9.6), n=45 
(Figure 2a). This inotrope insensitivity persisted for at least 15 minutes after IL-6 was removed from the 
perfusion buffer.  
We previously showed meningococcal serum had both acute and latent myocardial depressant effects [31]. 
Similarly, IL-6 significantly reduced contraction amplitude of cardiac myocytes following incubation (48 
hours), with a median (IQR) percentage change in contraction amplitude of -24.2% (-4.9 to -56.3)     
compared to control cells, n=14, p=0.03.  
JAK2 and PI3K/Akt are involved in IL-6 induced negative inotropy 
Activation of JAK/STAT signaling has previously been associated with gp130-related stimulation by IL-6 in 
adult ventricular cardiac myocytes [16]. Addition of AG490 (a specific inhibitor of Jak 2) to the perfusion 
buffer reduced the negative inotropic effect of IL-6 on isoprenaline-stimulated myocytes: Median (IQR) 
change in contraction amplitude of -9.8% (-22.5 to -2) (control) to -0.85% (-18.5 to 10.2), n=9(JAK2-
inhibited), although the change was not statistically significant (Figure 2b). Further, STAT3 phosphorylation 
was not significantly increased. Median (IQR) ratio of phosphorylated to total STAT3 in control cells was 
0.381 (0.17-0.60) and in IL-6 exposed cells was 0.39 (0.22-0.93), n=10 p=0.06. This suggests that pathways 
other than JAK/STAT may be involved.  
Several groups have implicated PI3K in the negative regulation of cardiac contractility [18, 32]. In 
agreement with these previous findings, we found that the PI3 Kinase inhibitor LY294008 ablated the 
myocardial depressant effect of IL-6. Control cells had a median (IQR) change of -17.8% (-46.6 to -8.2), n=6 
in contraction amplitude, whilst pre-treatment of myocytes with LY294008, resulted in no significant 
change (Median, IQR: 0.1; -6.8 to 5.8) in contraction amplitude following exposure to IL-6 (n=5), (Figure 
2b). In addition, in myocytes exposed to IL-6, phosphorylation of Akt, a downstream signaling protein in 
the PI3K pathway was increased by 1·5 fold over control cells (Figure 2c). 
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p38MAPK regulates inotrope insensitivity in IL-6 exposed myocytes. 
We used the p38MAPK inhibitor, SB203580, to investigate the role of p38MAPK in IL-6-induced negative 
inotropy. Pretreatment with SB203580 not only inhibited IL-6-induced myocardial depression, but restored 
isoprenaline responsiveness in both rat and human myocytes (Fig. 1d). In rat myocytes, a reduction in 
contractility of control cells (median, IQR -15%, -27.7 to -5.7) compared to isoprenaline alone was 
converted to a (median, IQR 5.6%, -3 to 56.5) increase in contractility in response to IL-6 in SB203580-
exposed cells (again compared to contractility with isoprenaline alone) (n=8). In human myocytes, IL-6 
reduced myocyte contractility (median, IQR -27.4, -41.8 to 0.8), but SB203580 pre-treatment led to a 
median increase in contraction amplitude of 107.1 (IQR 93.5 to 116.1) following IL-6-exposure (n=7). There 
was no effect of any of the inhibitors on basal myocyte contraction amplitude or on the response to 
isoprenaline (data not shown). This is to our knowledge the first study to demonstrate in human cardiac 
myocytes that inhibition of p38MAPK reverses IL-6-mediated contractile depression. Indeed in the absence 
of p38MAPK activity, IL-6 had a paradoxical effect and increased myocyte contractility. 
To confirm the key role of the p38MAPK pathway in the negative inotropy of IL-6, rat myocytes were 
transfected with an adenovirus encoding a dominant negative p38MAPK (p38DN), to reduce p38MAPK 
activity. Western blotting confirmed that transduced cells showed greatly reduced p38MAPK 
phosphorylation, although a small amount of residual p38MAPK phosphorylation was retained (data not 
shown). P38DN myocytes were also resistant to the negative inotropy of IL-6 (Fig. 2d). In control cells, IL-6 
exposure reduced contraction amplitude (median, IQR -13.1, -29 to -2.9). In p38DN myocytes, IL-6 induced 
no significant change in contraction amplitude (median;IQR 5.35% -9.7 to 10.7, n=10), confirming the 
importance of p38MAPK in the myocardial depressant activity of IL-6.  
Finally, we investigated changes in gene expression of the p38MAPK pathway in cardiac myocytes exposed 
to IL-6. Adult rat ventricular myocytes were cultured with recombinant human interleukin 6 for a period of 
6 hours. 740 genes were significantly differentially expressed (fold change of treated cells compared to 
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control cells of p<0.05) (supplementary table 1). Of these, 8 genes belonged to the p38-MAPK pathway 
(out of 115 MAPK-associated genes represented on the array). The hypergeometric probability of this 
occuring by chance was p=0.004. Table 1 lists these genes, their log fold changes and p-values. Taken 
together, our data establish an important functional role for p38MAPK signaling in the negative inotropic 
activity of IL-6. It is interesting to note that in the absence of p38MAPK activity, the net effect of IL-6 on rat 
myocytes was positive inotropy. 
 
p38MAPK is highly dysregulated in children with meningococcal sepsis. 
As shown in Figure 2, a large proportion of genes of the p38MAPK pathway were significantly differentially 
expressed in children with meningococcal septicaemia compared to healthy controls. Hierarchical 
clustering of p38 MAPK genes and subjects showed that patients and controls showed significant 
differentiation in the levels of expression of p38MAPK pathway genes (Figure 4a). Of the 150 MAPK genes 
on the array, 115 were differentially expressed. In order to examine those genes of this pathway which 
best discriminated patients from controls we displayed the data on a volcano plot as demonstrated in 
Figure 4ď. pϯ8MAPKα ;MAPKϭϰͿ, the isoforŵ ŵost ĐoŵŵoŶlǇ assoĐiated ǁith Ŷegatiǀe iŶotropǇ had a high 
log odds (17·54) and significance (adjusted p value=7·88x10
-10
) in patients compared to healthy controls. In 
addition, a large number of genes upstream and downstream of p38MAPK showed significant differential 
expression in children with severe meningococcal infection on admission to intensive care, relative to 
expressed levels of these genes in healthy controls (Figures 4a and 4b and Supplementary Figure 1; 
Supplementary table 2). The probability that this group of p38MAPK genes was differentially expressed by 
chance was 2·12 x10e-11 (calculated using the hypergeometric distribution), which strongly supports the 
hypothesis that the differential regulation of the p38MAPK pathway is a key feature of meningococcal 
sepsis.  
Discussion 
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Interleukin 6 is an established mediator of organ dysfunction in septic shock. We and others have 
highlighted the role of IL-6 in the pathogeneisis of organ dysfunction in children with septicaemia [12, 33]. 
In a murine cecal ligation and puncture model of septic shock, levels of IL-6 at 6 hours following onset of 
sepsis were predictive of outcome [34]. Whilst the effect of Il-6 on cardiac myoctes has largely been 
assumed to be due to transignaling from binding of IL-6 to soluble receptor in serum and subsequent 
activation via cell surface gp130 receptor, our data in both rat and human cardiac myocytes show a direct 
negative inotropic effect of IL-6 in the absence of the soluble receptor [12], suggesting that classical 
signaling via a cell surface IL-6 receptor also occurs.  
Our study has demonstrated that the myocardial depressant effects of IL-6 appear to be dependent on 
signaling through the p38MAPK pathway, and that inactivation of p38MAPK abolishes this activity, and 
restores sensitivity to the inotropic agent isoprenaline.  
P38MAPK regulates a broad range of cellular responses, including inflammation, proliferation, apoptosis, 
cellular defense and differentiation [35, 36]. Activation of p38MAPK has been demonstrated in myocardial, 
lung and brain tissue in sepsis [37-40], suggesting that p38MAPK has widespread effects in the 
pathophysiology of multi-organ dysfunction in septic shock. Inhibition of p38MAPK has been shown to 
attenuate LPS-induced acute lung injury through downregulation of the NFKB pathway [41].  
In animal models, the p38MAPK pathway has been shown to contribute to the cardiodepressant activity of 
TNFα [17] and endotoxin [42]. During myocardial ischemia and reperfusion, p38MAPK activation induces 
myocyte apoptosis, increases expression of adhesion molecules, and reduces cardiac myofilament calcium 
sensitivity [43]. Moreover, iŶhiďitioŶ of pϯ8MAPK preǀeŶts ŵǇoĐardial TNFα eǆpressioŶ aŶd iŵproǀes 
cardiac function and survival in endotoxemic rats [42].  
Our RNA expression studies in children with meningococcal sepsis has revealed elevated abundance of 
transcripts for genes that encode upstream activating factors for p38 MAPK (MAP3K7, MAP3K5, MAP2K4 
and MAP2K6); the IL6 receptor; JAK2 and Akt, as well as downstream mediators, including transcription 
factors (such as Nuclear Factor KappaB and Activating Transcription Factor), MAPK activated protein 
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kinases and Inflammatory cytokines such as IL-ϭβ.  These data confirm that the p38 MAPK pathway is 
highly activated in acute meningococcal sepsis in humans. Data from the Genomics of Pediatric SIRS/Septic 
Shock Investigators confirms in a larger group of children with septic shock that the IL-6 and p38MAPK 
pathways are significantly dysregulated on admission to PICU [44]. 
 
We have demonstrated that the p38MAPK pathway is dysregulated in cardiac myocytes following exposure 
to IL-6, and that the negative inotropy of IL-6 is reversed by blockade of the p38MAPK pathway. Our data 
suggest that the p38MAPK pathway is of major importance in the development of inotrope-
unresponsiveness both acutely and after a prolonged incubation time.  The  dramatic effect of inhibitors of 
P38MAPK not only in abolishing the myocardial depressant effect of IL6 on cardiac contractility in vitro, but 
in restoring inotrope sensitivity, suggests that inhibition of p38MAPK may be of benefit in treatment of 
meningococcal shock, as the condition is characteristically associated with reduced inotrope responses, 
and the requirement for escalating doses of catecholamines. Other inflammatory mediators known to have 
myocardial depressant effects such as the complement component C5a and the pro-inflammatory cytokine 
TNFα haǀe also ďeeŶ shoǁŶ to aĐtiǀate the pϯ8MAPK pathǁaǇ [45, 46].  
An important limitation of our study is the unavailability of human septic myocardial tissue. Checchia et al 
examined the effects of age on transcriptional responses to sepsis in the myocardium of young (6 weeks) 
and old (20 months) septic mice. Genes of the IL-6 and p38MAPK pathway were among 53 significantly 
differentially expressed genes comparing young and old sepsis and sham groups of animals [47].  
As IL-6 is released in response to all bacterial infections, our findings may be relevant to the treatment of 
myocardial depression in other forms of septic shock. In children with septic shock of varying etiology 
(both Gram positive and Gram negative), Cvijanovich identified the p38MAPK pathway being significantly 
upregulated [48]. Furthermore, our findings may also be relevant to other forms of systemic inflammatory 
activation such as burns [49], ischemia-reperfusion [50] and cardiopulmonary bypass [51, 52], where 
p38MAPK activation and its relation to multi-organ dysfunction is becoming increasingly clear. Inhibitors of 
the p38MAPK pathway are being investigated in animal and human studies of sepsis and other pro-
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inflammatory disease states [52-56]. Modulation of up- or downstream regulators of this pathway could 
also be of interest therapeutically. 
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Figure Legends: 
Figure 1: Experimental approach to studying the pathway of IL-6 induced myocardial depression 
We utilised both an in vitro model of cardiac function to explore the mediators activated by IL-6 (1a) and 
blood samples from children with meningococcal sepsis to examine changes in the regulation of the 
p38MAPK pathway (1b). 
Figure 2: Pathway analysis of IL-6 mediated cardiac dysfunction 
JAK2, PI3K, Akt and p38MAPK modulate the negative inotropic response of cardiac myocytes to IL-6.  a. 
Acute effect of IL-6 on cardiac myocyte contractility. Measurements were taken in the presence of 
perfusion buffer alone (baseline) and then following addition of 30nM Isoprenaline to the buffer 
(isoprenaline stimulation), addition of 20ng/ml IL-6 to the perfusion buffer (addition of IL-6), and removal 
of IL-6 from the buffer (IL-6 washout).  b. Role of JAK2 and PI3K in IL-6 induced myocyte contractile 
depression. The difference in contractility of cardiac myocytes in the presence of isoprenaline and IL-6 was 
measured with and without a JAK2 or PI3K inhibitor. IL-6 depressed contractility, and this depression was 
reversed by inhibition of JAK2 using AG490, or by inhibition of PI3K using LY294008.  c. IL-6 increases 
phosphorylation of Akt in rat cardiac myocytes. Western blots demonstrate increased phosphorylation of 
AkT (pAkt) in rat cardiac myocytes incubated with IL-6 compared to control cells.  d. Role of p38MAPK in IL-
6 induced myocyte contractile depression.  Inhibition of p38MAPK using SB203580 not only reversed the 
negative inotropic effect of IL-6 in both rat (i) and human (ii) cardiac myocytes, but a positive inotropic 
activity was seen in response to IL-6 in these cells. In addition, in p38 Dominant Negative myocytes, the 
effect of IL-6 was significantly diminished. 
 
Figure 3: Genes of the p38MAPK pathway are differentially regulated in meningococcal sepsis 
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Schematic diagram showing the genes that encode key members of the p38MAPK signaling pathway, 
showing upstream triggers and downstream effector molecules of p38MAPK (MAPK14). Genes with 
significantly elevated transcript levels in patients are shown in red, genes with significantly decreased 
transcript levels are shown in green, while non-differentially expressed genes are shown in black. Genes 
that were dysregulated in cardiac myocytes following exposure to IL-6 are marked with an asterisk. 
 
Figure 4: The p38MAPK pathway is significantly dyregulated in blood from septic patients compared to 
healthy controls.  a. Heatmap of gene expression patterns in whole blood from meningococcal patients 
compared to control patients. Patterns of transcript abundance of genes involved in the p38MAPK 
pathway in whole-blood samples from 14 children with meningococcal sepsis compared to 23 healthy 
adults. Genes and subjects were organized using hierarchical clustering; each row represents a single gene, 
and each column a single subject (sample). Black indicates the median level of transcript abundance, red 
indicates higher transcript abundance than the median, green, lower transcript abundance, and white, 
missing data. The genes in the heatmap are listed in supplementary table 1.  b. Log-odds ratios of 
differentially expressed genes of the p38MAPK pathway in meningococcal patients compared to healthy 
children. The volcano plot arranges genes along dimensions of biological and statistical significance. The 
horizontal axis is the average log fold difference between meningococcal patients and the healthy controls 
for genes of the p38MAPK pathway. The vertical axis is the log-odds ratio that the gene is differentially 
expressed, and indicates the statistical evidence, or reliability of the difference.  
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Table 1.  Differentially expressed genes of the p38MAPK pathway in cardiac myocytes exposed to IL-6.  
Changes in transcript levels of differentially expressed genes associated with the p38MAPK pathway in rat 
cardiac myocytes exposed to interleukin 6. ͞logFC͟ is the log2 fold difference between IL-6 treated and 
untreated cardiac myocytes. ͞adj.P.Val͟ is the associated p-value before and after adjustment for multiple 
testing. Genes are ordered by the magnitude of the adjusted p value. 
22 
 
Supplementary Figure 1. Boxplots showing significantly regulated genes of the p38MAPK pathway.  a. 
Upregulated genes of the p38MAPK pathway. Genes that encode members of the p38MAPK pathway that 
are significantly over-expressed in meningococcal patients as compared to healthy children.  b. 
Downregulated genes of the p38MAPK pathway.  Genes that encode members of the p38MAPK pathway 
that are significantly under-expressed in meningococcal patients as compared to healthy children. 
 
Supplementary Table 1.  List of all differentially expressed genes in rat cardiac myocytes exposed to IL-6. 
͞logFC͟ is the log2 fold difference between cases and controls. ͞t” is the moderated t-statistic[22]. 
͞adj.P.Val͟ is the associated p-value before and after adjustment for multiple testing. ͞B-statistic͟ is the 
log-odds that the gene is differentially expressed[22]. Genes are ordered by magnitude of the adjusted p 
value, and are identified by official gene symbol (Gene ID, column A) and by the Illumina Probe number 
(column B). 
 
Supplementary Table 2. Summary statistics of changes in expression of p38MAPK pathway genes.   
List of differences in transcript levels for genes associated with the p38MAPK pathway and differentially 
expressed in children with and without meningococcal sepsis. ͞logFC͟ is the log2 fold change between 
cases and controls. ͞t” is the moderated t-statistic[22]. ͞adj.P.Val͟ is the associated p-value before and 
after adjustment for multiple testing. ͞B-statistic͟ is the log-odds that the gene is differentially 
expressed[22]. Genes are ordered by log fold change. 
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Table 1: list of differentially expressed genes of the p38MAPK 
pathway in cardiac myocytes exposed to IL-6
Gene symbol Gene name log Fold change adj.P.Val
JUND Jun D proto-oncogene -0.366 0.001
ZFP36 zinc finger protein 36 -0.381 0.009
AKT1 v-akt murine thymoma viral oncogene homolog 1 -0.440 0.013
FAS Fas (TNF receptor superfamily, member 6) 0.148 0.015
MAPK8 Mitogen-activated protein kinase 8 0.130 0.037
SOS2 Son of sevenless homolog 2 0.104 0.043
ECSIT
Evolutionarily conserved signaling intermediate in Toll 
pathway -0.177 0.044
DUSP12 Dual specificity phosphatase 12 -0.163 0.046
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